RE:RE:RE:RE:Oakville - show some leadership please provide an updateLatice, Third-party pharmaceutical data base called Medi-Span indicates what generics are up in the cue from the fda. I'm not sure if you get your information from that site. When management said the new generics on the scene were "unexpected" I almost spit out my coffee. Maybe I should suggest that he purchase a subscription to Medi-Span before Q3 ? This management team is nothing but bald faced liars and the class action lawyers are all just chomping at the bit ready to nuke them.
LaticelnExile wrote: rad10 wrote: Dont you think with the release of the CFO every bit of bad news was thrown into the last quarter? (OK half a billion is a lot of bad news) I would not be short CXR at this point (10 bucks and change).
Expect further write downs if it makes it to Q3. The amortization period for their legacy portfolio was far too long as their drugs are not enduring assets (despite that management commentary said when they purchased them that they had a "steady revenue stream") While Donnatal is at regulatory risk for being pulled because of phenobarbital side effects and Concordia's ommisison of supplemental clinical data that proves ts efficacy, it has almost become a moot for the short thesis because sales of Donnatal are being crushed organically by big pharama at the counter. Donntaal currently holds less than 1.6% of the IBS market share and has been steadily declilning. In the con call, management said that they hoped that Donnatal sales would be flat. I am betting that "flat" is optimistic. Other key drugs in the NA portfolio - Dyrenium and Zonegran scripts are fading. I am going on record to say that I anticipate a write down on these two drugs to come. Concordia's model has been to buy "unloved" old drugs that they thought no one would want to compete against. That is proving wrong ... generics are pushing their drugs down hard.